title: Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
abstract: Chemotherapy sometimes results in induction of specific antitumor immunity. We investigated the mechanisms responsible for the induction of antitumor immunity in mice bearing MOPC-104E plasmacytoma after chemotherapy with cisplatin (CDDP), especially the effects of CDDP on the expression of MHC on the tumor surface. BALB/c mice were subcutaneously (s.c.) inoculated with MOPC-104E cells on day 0, then intravenously (i.v.) treated with CDDP at 3.6 mg/kg on day 7. The tumors disappeared completely on day 35 and the mice rejected a second challenge with MOPC-104E, but did not reject syngeneic Meth-A fibrosarcoma. The tumors did not regress, however, when MOPC-104E was s.c. transplanted in nude mice, or when anti-T-cell monoclonal antibodies were i.v. injected into BALB/c mice before CDDP treatment on day 6. To determine which of the mice or tumor were affected by CDDP, BALB/c mice were inoculated with CDDP-treated (12.5 micrograms/ml for 3 hours in vitro) MOPC-104E cells on day 0, 7 and 14. The potential to reject MOPC-104E was lower in mice immunized with ethanol-treated MOPC-104E cells than in those immunized with CDDP-treated cells. CDDP-treated or -untreated MOPC-104E cells ultrasonicated and fractionated into soluble and insoluble fractions by centrifuging, also induced antitumor immunity. Flow cytometry demonstrated that the expression of MHC-class-I antigens H-2Dd and H-2Kd was enhanced after CDDP-treatment, but that of class-II antigens I-Ad and I-Ed was not, suggesting that CDDP induced tumor-specific antitumor immunity by enhancing the expression of MHC-class-I antigens.
authors.affiliation: First Department of Surgery, Shimane Medical University, Izumo, Japan. fsurgery@shimane-med.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Nio
authors.forename: N
authors.initials: N
authors.lastname: Hirahara
authors.forename: Y
authors.initials: Y
authors.lastname: Minari
authors.forename: C
authors.initials: C
authors.lastname: Iguchi
authors.forename: K
authors.initials: K
authors.lastname: Yamasawa
authors.forename: T
authors.initials: T
authors.lastname: Toga
authors.forename: K
authors.initials: K
authors.lastname: Tamura
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002453:Cell Cycle; D002458:Cell Fractionation; D002945:Cisplatin / Q000627:therapeutic use*; D005434:Flow Cytometry; D006183:H-2 Antigens / Q000096:biosynthesis; D064532:Histocompatibility Antigen H-2D; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D008212:Lymphocyte Depletion; D008285:Major Histocompatibility Complex; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010954:Plasmacytoma / Q000188:drug therapy* / Q000276:immunology*; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination
chemical_list: D000970:Antineoplastic Agents; D006183:H-2 Antigens; C024755:H-2K(K) antigen; D064532:Histocompatibility Antigen H-2D; D000949:Histocompatibility Antigens Class II; C111389:I-Ad antigen; C024138:I-E-antigen; D002945:Cisplatin